China’s New Legal Power To Limit Or Block Mergers Could Signal Challenges For Global Pharmaceutical Alliances

Armed with a new antitrust law, the Ministry of Commerce could derail megamergers of companies with an interest in China, like Pfizer/Wyeth, slated to be completed later this year.